A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination

References

• The global impact of respiratory diseases [Internet]. Forum of international respiratory societies-second edition. Sheffield: European Respiratory Society; 2017 [cited 2020 Sep 7]. Available from: https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf
   Google Scholar
• The Global Asthma Report 2018 [Internet]. Global asthma report; [cited 2020 Aug 14]. Available from: http://wglobalasthmareport.org/burden/burden.php
   Google Scholar
• Chronic obstructive pulmonary disease (COPD) [Internet]. World Health Organization; 2017; [cited 2020 Aug 14]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
   Google Scholar
• Celli BR. Update on the management of COPD. Chest. 2008;133(6):1451–1462.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405–1411.
   PubMed Web of Science ®Google Scholar
• van Noord JA, Schreurs AJ, Mol SJ, et al. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax. 1999;54(3):207–212.
   PubMed Web of Science ®Google Scholar
• Global strategy for asthma management and prevention [Internet]. Global initiative for asthma; 2020 [cited 2020 Oct 10]. Available from: https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf
   Google Scholar
• Global strategy for the diagnosis, management, and prevention of COPD-A 2021 report [Internet]. Global initiative for chronic obstructive lung disease; [cited 2020 Dec 28]. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pd
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–537.
   PubMed Web of Science ®Google Scholar
• Corren J, Tan R. Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform®) for the treatment of asthma. Drug Des Devel Ther. 2014; Internet 1555 DOI:https://doi.org/10.2147/DDDT.S36556
   Google Scholar
• Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs. 1991;42(1):115–137.
   PubMedGoogle Scholar
• Cheer SM, Scott LJ. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med. 2002;1(4):285–300.
   PubMedGoogle Scholar
• Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26):2145–2160.
   PubMed Web of Science ®Google Scholar
• Foradil MDDPI, Skyehaler F, Formoterol dry-powder inhalation–Novartis/SkyePharma. Drugs R D. 2004;5(3):162–163.
   PubMedGoogle Scholar
• Maesen BLP, Westermann CJJ, Duurkens VAM, et al. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. Eur Respir J. 1999 May;13(5):1103.
   PubMedGoogle Scholar
• Cazzola M, Santangelo G, Piccolor A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1994;7(2):103–107.
   PubMedGoogle Scholar
• Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(2):205–215.
   PubMedGoogle Scholar
• Phillipps GH. Structure-activity relationships of topically active steroids: the selection of Fluticasone propionate. Respir Med. 1990;84:19–23.
   PubMed Web of Science ®Google Scholar
• Mackie AE, McDowall JE, Ventresca P, et al. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing ChloroFPorocarbon or HydroFPoroalkane propellant. Clin Pharmacokinet. 2000;39:17–22.
   PubMedGoogle Scholar
• McKeage K. Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma. Drugs. 2013 Feb;73(2):195–206.
   PubMedGoogle Scholar
• Mitzutani T, Morise M, Ito Y, et al. Nongenomic effects of fluticasone propionate and budesonide on human airway anion secretion. Am J Respir Cell Mol Biol. 2012;47(5):645–651.
   PubMedGoogle Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index: inhaled corticosteroids potency and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380.
   PubMed Web of Science ®Google Scholar
• Nathan RA, D’Urzo A, Blazhko V, et al., Safety and efficacy of Fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulm Med. 12(1): 67. 2012.
   PubMedGoogle Scholar
• Corren J, Mansfield LE, Pertseva T, et al. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med. 2013;107(2):180–195.
   PubMed Web of Science ®Google Scholar
• Płoszczuk A, Bosheva M, Spooner K, et al. Efficacy and safety of Fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial. Ther Adv Respir Dis. 2018;12:175346661877792.
   Google Scholar
• Pearlman DS, LaForce CF, Kaiser K. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clin Ther. 2013;35(7):950–966.
   PubMedGoogle Scholar
• Pertseva T, Dissanayake S, Kaiser K. Superiority of Fluticasone propionate/formoterol fumarate versus Fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial. Curr Med Res Opin. 2013;29(10):1357–1369.
   PubMed Web of Science ®Google Scholar
• Antilla M, Castro F, Cruz Á, et al. Efficacy and safety of the single-capsule combination of Fluticasone/formoterol in patients with persistent asthma: a non-inferiority trial. J Bras Pneumol. 2014;40(6):599–608.
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, van Noord J, Schröder-Babo W, et al. Efficacy and safety profile of Fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial. Curr Med Res Opin. 2013;29(5):579–588.
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Pulka G, Dymek A, et al., Efficacy and safety of Fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med. 105(5): 674–682. 2011.
   PubMed Web of Science ®Google Scholar
• Balki A, Balamurugan S, Bardapurkar S, et al. Comparison of Fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: results from a 12-week randomized controlled trial. Pulm Pharmacol Ther. 2018;48:28–36.
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Buhl R, Balint B, et al. Fluticasone/Formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma. 2012;49(10):1060–1070.
   PubMedGoogle Scholar
• Cukier A, Jacob CMA, Rosario Filho NA, et al. Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma. Respir Med. 2013;107(9):1330–1338.
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Dymek A, McAulay K, et al. Fluticasone/formoterol combination therapy is as effective as Fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11(1):28.
   PubMed Web of Science ®Google Scholar
• Wan YMS, Haughney J, Small I, et al. Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: a real-life effectiveness and cost impact evaluation. Respir Med. 2017;129:199–206.
   PubMedGoogle Scholar
• Emeryk A, Klink R, McIver T, et al. A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of Fluticasone propionate/formoterol in children with asthma. Therapeut Adv Respir. 2016;10(4):324–337.
   PubMedGoogle Scholar
• McIver T, Emeryk A, Klink R, et al. Fluticasone propionate/Formoterol fumarate (FPT/FORM) combination therapy has comparable efficacy to Fluticasone propionate/salmeterol xinafoate (FPT/SAL) in paediatric patients with asthma. Eur Respir Soc. 2011;38(55):4822.
   Google Scholar
• Aalbers R, Brusselle G, McIver T, et al., Onset of bronchodilation with Fluticasone/Formoterol combination versus Fluticasone/Salmeterol in an open-label, randomized study. Adv Ther. 29(11): 958–969. 2012.
   PubMedGoogle Scholar
• Rattu A, Kaur I, Goel A, et al. The comparison of clinical efficacy of formoterol and Fluticasone versus salmeterol and Fluticasone in patients of bronchial asthma. Int J Basic Clin Pharmacol. 2018;7(5):947.
   Google Scholar
• Ghoshal A, Waghray P, Dsouza G, et al. Real-world evaluation of the clinical safety and efficacy of Fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India. Pulm Pharmacol Ther. 2020;60:101869.
   PubMedGoogle Scholar
• Schmidt O, Petro W, Hoheisel G, et al. Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – results from a non-interventional study. Respir Med. 2017;131:166–174.
   PubMed Web of Science ®Google Scholar
• Papi A, Dokic D, Tzimas W, et al. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. COPD. 2017;12:1961–1971.
   Google Scholar
• Bollmeier S, Prosser T. Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma. Therap Clin Risk Manag. 2015;889. DOI:https://doi.org/10.2147/TCRM.S55116
   Google Scholar
• Maxiflo inhaler (Formoterol fumarate + Fluticasone propionate) [Internet]. [cited 2020 Nov 12] Available from: https://www.ciplamed.com/content/maxiflo-inhaler
   Google Scholar
• Balamurugan S, Apte K. Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDI. Respir Med. 2020;161:105707.
   PubMed Web of Science ®Google Scholar